Many studies have demonstrated that defactinib effectively inhibits in various types of FAK-overexpressing cancers by effectively blocking the PI3K/AKT and downstream signaling (Zhang B Y et al., 2021; Cuellar-Vite et al., 2022; Liu et al., 2024). Here, AKT1 is linked to cancer.